Supplemental Figures
: A, Known characteristics of patient-derived samples evaluated in Figure 6 .
Supplemental Figure 1 : A, Comparison of maximum inhibition values for 10 AML cell lines treated with a titration of GSK2879552 for 6 (x-axis) and 10 (y-axis) days. B, Comparison of EC50 values for 10 AML cell lines treated with a titration of GSK2879552 for 6 (x-axis) and 10 (y-axis) days. C, Cell cycle phase distribution of MOLM-13 cells treated with a titration of GSK-LSD1 for 6 days. D, Representative flow cytometric histograms of CD11b protein expression on THP-1 cells (left) and CD86 protein expression on MOLM-13 cells (right) treated with GSK2879552 for 1 day. E, Representative dose response curves of CD11b protein expression on THP-1 cells (top) and CD86 protein expression on MOLM-13 cells (bottom) treated with GSK2879552 for 1 day. F, The change (treatment-vehicle) in the percentage of cells positive for CD86 (blue), CD11b (red), and CD71 (green) protein expression (+/-standard error) for 6 AML cell lines treated with 500 nM GSK2879552 (or 1000 nM GSK2879552 for CD86 and CD11b only, indicated by *) for 3 days. Significance (p < 0.05) between DMSO and GSK552 treatment is indicated with a †.
Supplemental Figure 2 : A, Percent maximum inhibition (blue bars) +/-standard error and IC50 values (red circles) +/-standard error for AML cells treated with a titration of GSK2879552 +/-1, 10, 100, or 1000 nM ATRA for 4 days. Significance (p < 0.05) between DMSO and ATRA treatments is represented as * for maximum inhibition and as † for IC50. Higher concentrations of ATRA for SIG-M5 were not evaluable. Table 2 : A-B, Values based on Bliss Independence analysis for 7 AML cell lines treated with indicated concentrations of GSK2879552 and ATRA for 4 days (A) and 6 days (B). Values > 20, representing strong synergy, are colored dark green. Values > 10 -20, representing weak synergy, are colored light green. Values < -10, representing antagonism, are colored gold. Figure 3 : A, Venn diagrams depicting the overlap of significantly differentially expressed genes in the specific treatments (GSK2879552 + ATRA combination relative to DMSO, ATRA relative to DMSO and GSK2879552 relative to DMSO) for MV4-11, HL-60, THP-1, and Kasumi-1 cell lines. The top row shows day 2 samples, and bottom row shows day 4 samples. B, Corresponding gene expression heatmaps depicting the union of genes from day 2 and day 4 Venn diagrams (from A) for MV-4-11, THP-1, HL-60 and Kasumi-1 cell lines. Values are row-mean centered, log2 normalized, gene expression data shown high (yellow) to low (blue). Top row indicates treatment type DMSO, GSK2879552, ATRA or GSK2879552 + ATRA combination in tan, magenta, salmon and green, respectively. Bottom row indicates day 2 in black and day 4 in red. C, Gene expression fold change relative to DMSO from RNA-seq study and from qRT-PCR validation. D, Colorplot indicating the significantly enriched KEGG pathways (MSigDB) as determined using the central limit theorem separated by day for combination relative to DMSO. Adjusted p-values are shown for pathways that were significant in at least one condition (day, cell line). Color indicates the level of significance from adjusted p-value 0.1 in white to 0 in red. Significance values for day 2 is shown in the top panel and day 4 in the bottom panel. E, Barplots showing the top 10 KEGG pathways found to be significantly enriched from significantly differentially expressed genes for each treatment relative to DMSO for each cell line (union of day 2 and day 4 genes). Bars show the -log(FDR p-value) on the x-axis and the top ten MSigDB KEGG pathways identified as enriched in at least one treatment on the y-axis. Figure 4 : A, Percent CD11b+ expression (blue bars) on AML cell lines treated with the indicated concentrations of GSK2879552 and ATRA for 2 days. The value representing the predicted additive effect at each combination concentration is indicated with a red circle. B, Representative histograms of CD11b expression on THP-1 cells treated with DMSO (green), 1000 nM GSK2879552 (orange), 100 nM ATRA (blue), or 1000 nM GSK2879552 plus 100 nM ATRA (red) for 2 days. C, Shading represents median fluorescence intensity values of CD11b expression relative to additive threshold on THP-1 cells treated with the indicated concentrations of GSK2879552 and ATRA for 2 days. Dark green shading indicates > 10-fold above additive threshold, light green indicates > 5 -10 fold above additive threshold, light brown indicates 1 -5 fold above additive threshold. D, May Grunwald/Giemsa staining of MOLM-13 cells treated for 3 days with DMSO, 500 nM GSK-LSD1, 1000 nM ATRA, or the combination of 500 nM GSK-LSD1 plus 1000 nM ATRA. Supplemental Table 4 : A, EC50 values of dose response curves for cell lines treated for two days with a titration of GSK2879552 plus and minus the indicated concentration of ATRA. Figure 5 : A, GDI values of AML cell lines treated with 1000 nM GSK2879552, 100 nM ATRA, or 1000 nM GSK2879552 + 100 nM ATRA for 1 to 6 days. Significance (p < 0.05) is indicated by † between GSK552 and COMBO; by ‡ between ATRA and COMBO; and by * between both GSK552 and COMBO as well as ATRA and COMBO. Cells must reach a minimum doubling of 0.75 to be evaluated. B, Fold caspase 3/7 cleavage values from day of peak induction (blue bars) for AML cell lines treated with the indicated concentrations of GSK2879552 and ATRA. The value representing the additive effect at each combination concentration is indicated with a red circle. C, Annexin V staining of MOLM-13 cells treated for 3 days with a titration of GSK-LSD1, a titration of ATRA, or a titration of GSK-LSD1 plus 1000 nM ATRA. D, Annexin V and CD11b staining of MOLM-13 cells treated for 1-3 days with the indicated concentrations of GSK-LSD1 or ATRA. Figure 6 : A, Maximum percent of inhibition achieved for 9 AML patient samples treated with a titration of GSK2879552 +/-100 nM ATRA or 100 nM ATRA. B, IC50 values of the GSK2879552 dose response curves +/-100 nM ATRA for 9 AML patient samples. 10 0 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 Q1 0% 
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